BioSpace

ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ expectations for recurrence-free survival, leaving questions as to its applicability to tumor types beyond melanoma.

By BioSpace

1 min read
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights